| Cancer name | Skin Cutaneous Melanoma |
| Cancer Type | SKCM |
| Immunotherapy type | Cancer Vaccine |
| Treatment | DC vaccine(Dendritic Cell vaccine) |
| Drugstatus | NA |
| Drugbank ID | NA |
| Checkpoints | NA |
| Signature Type | Protein |
| Signature | PEBP1 |
| Official Symbol | PEBP1 |
| Mode of action | PROT_R_UP |
| Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals. | |
| Experimental | clinical trial phase 1/2 |
| Description | Only one of these genes, PEBP1 (RKIP) correlated positively with patient survival; the remaining three, FCGR1B (CD64), ANXA2 (Annexin-2) and FCGR1B (Fcγ-receptor 1B, CD64), correlated negatively. Interestingly, for PEBP1 the expected positive correlation with survival time, as well as a significantly lower expression in PBMCs from short surviving patients, was observed in validation samples from both treatment centers. For FCGR1B, a trend for negative association with survival was observed, but only in the Nijmegen validation cohort . However, the association of ANXA2 and IMPA2 could not be confirmed in any of these samples: they were neither differentially expressed between long and short survivors in the additional Nijmegen samples, nor in the completely independent Copenhagen samples. |
| PMID | 28978044 |
| Title | Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein |